FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2186259675> ?p ?o ?g. }

• W2186259675 abstract "Objective: To assist women and their physicians in making decisions regarding the prevention of breast cancer with tamoxifen and raloxifene. Evidence: Systematic review of English-language literature published from 1966 to August 2000 retrieved from MEDLINE, HealthSTAR, Current Contents and Cochrane Library. Values: The strength of evidence was evaluated using the methods of the Canadian Task Force on Preventive Health Care and the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Recommendations: • Women at low or normal risk of breast cancer (Gail risk assessment index < 1.66% at 5 years): There is fair evidence to recommend against the use of tamoxifen to reduce the risk of breast cancer in women at low or normal risk of the disease (grade D recommendation).  Women at higher risk of breast cancer (Gail index ≥ 1.66% at 5 years): Evidence supports counselling women at high risk on the potential benefits and harms of breast cancer prevention with tamoxifen (grade B recommendation). The cutoff for defining high risk is arbitrary, but the National Surgical Adjuvant Breast and Bowel Project P-1 Study included women with a 5-year projected risk of at least 1.66% according to the Gail index, and the average risk of patients entered in the trial was 3.2%. Examples of high-risk clinical situations are 2 first-degree relatives with breast cancer, a history of lobular carcinoma in situ or a history of atypical hyperplasia. As the risk of breast cancer increases above 5% and the benefits outweigh the harms, a woman may choose to take tamoxifen. The duration of tamoxifen use in such situations is 5 years based on the results from trials of tamoxifen involving women with early breast cancer. If a woman raises concerns or has already been evaluated and is calculated to be at high risk, then individuals experienced and skilled in counselling may discuss the potential benefits and harms of tamoxifen use. Important additional issues:  Prevention of breast cancer with raloxifene: Current evidence does not support recommending chemoprevention of breast cancer with raloxifene outside of a clinical trial setting.  Screening using the Gail risk assessment index: This index was the main eligibility criterion for enrolling women in the one study that showed potential benefit from chemoprevention. However, it has not been evaluated for use as a routine screening or case-finding instrument; validation of the index is required. Overall, current evidence does not support a shift to its routine use in physicians’ of" @default.
• W2186259675 created "2016-06-24" @default.
• W2186259675 creator A5025533495 @default.
• W2186259675 creator A5032526031 @default.
• W2186259675 creator A5034539129 @default.
• W2186259675 creator A5036535889 @default.
• W2186259675 date "2001-01-01" @default.
• W2186259675 modified "2023-10-04" @default.
• W2186259675 title "A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer" @default.
• W2186259675 cites W1966623655 @default.
• W2186259675 cites W1971022488 @default.
• W2186259675 cites W1990582579 @default.
• W2186259675 cites W2028037474 @default.
• W2186259675 cites W2055444502 @default.
• W2186259675 cites W2141647078 @default.
• W2186259675 cites W3016138847 @default.
• W2186259675 hasPublicationYear "2001" @default.
• W2186259675 type Work @default.
• W2186259675 sameAs 2186259675 @default.
• W2186259675 citedByCount "5" @default.
• W2186259675 crossrefType "journal-article" @default.
• W2186259675 hasAuthorship W2186259675A5025533495 @default.
• W2186259675 hasAuthorship W2186259675A5032526031 @default.
• W2186259675 hasAuthorship W2186259675A5034539129 @default.
• W2186259675 hasAuthorship W2186259675A5036535889 @default.
• W2186259675 hasConcept C121608353 @default.
• W2186259675 hasConcept C126322002 @default.
• W2186259675 hasConcept C142724271 @default.
• W2186259675 hasConcept C160735492 @default.
• W2186259675 hasConcept C162324750 @default.
• W2186259675 hasConcept C17744445 @default.
• W2186259675 hasConcept C199539241 @default.
• W2186259675 hasConcept C2777176818 @default.
• W2186259675 hasConcept C2779473830 @default.
• W2186259675 hasConcept C2780182762 @default.
• W2186259675 hasConcept C29456083 @default.
• W2186259675 hasConcept C50522688 @default.
• W2186259675 hasConcept C512399662 @default.
• W2186259675 hasConcept C530470458 @default.
• W2186259675 hasConcept C71924100 @default.
• W2186259675 hasConceptScore W2186259675C121608353 @default.
• W2186259675 hasConceptScore W2186259675C126322002 @default.
• W2186259675 hasConceptScore W2186259675C142724271 @default.
• W2186259675 hasConceptScore W2186259675C160735492 @default.
• W2186259675 hasConceptScore W2186259675C162324750 @default.
• W2186259675 hasConceptScore W2186259675C17744445 @default.
• W2186259675 hasConceptScore W2186259675C199539241 @default.
• W2186259675 hasConceptScore W2186259675C2777176818 @default.
• W2186259675 hasConceptScore W2186259675C2779473830 @default.
• W2186259675 hasConceptScore W2186259675C2780182762 @default.
• W2186259675 hasConceptScore W2186259675C29456083 @default.
• W2186259675 hasConceptScore W2186259675C50522688 @default.
• W2186259675 hasConceptScore W2186259675C512399662 @default.
• W2186259675 hasConceptScore W2186259675C530470458 @default.
• W2186259675 hasConceptScore W2186259675C71924100 @default.
• W2186259675 hasLocation W21862596751 @default.
• W2186259675 hasOpenAccess W2186259675 @default.
• W2186259675 hasPrimaryLocation W21862596751 @default.
• W2186259675 hasRelatedWork W1919199517 @default.
• W2186259675 hasRelatedWork W1964345762 @default.
• W2186259675 hasRelatedWork W2010369303 @default.
• W2186259675 hasRelatedWork W2086309252 @default.
• W2186259675 hasRelatedWork W2110510499 @default.
• W2186259675 hasRelatedWork W2117893731 @default.
• W2186259675 hasRelatedWork W2129022661 @default.
• W2186259675 hasRelatedWork W2141647078 @default.
• W2186259675 hasRelatedWork W2159079575 @default.
• W2186259675 hasRelatedWork W2163619128 @default.
• W2186259675 hasRelatedWork W2268337043 @default.
• W2186259675 hasRelatedWork W2337468944 @default.
• W2186259675 hasRelatedWork W2399411225 @default.
• W2186259675 hasRelatedWork W2409375848 @default.
• W2186259675 hasRelatedWork W2414661152 @default.
• W2186259675 hasRelatedWork W2418714734 @default.
• W2186259675 hasRelatedWork W2944418956 @default.
• W2186259675 hasRelatedWork W2971696111 @default.
• W2186259675 hasRelatedWork W3129351755 @default.
• W2186259675 hasRelatedWork W796060608 @default.
• W2186259675 isParatext "false" @default.
• W2186259675 isRetracted "false" @default.
• W2186259675 magId "2186259675" @default.
• W2186259675 workType "article" @default.